Research ExplorerPublicationsNeoplastic meningitis from breast cancer: feasibility and ac...

Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.

Standard

Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. / Hoffmann, Anna; Buhk, Jan Hendrik; Strik, H.

In: ANTICANCER RES, Vol. 29, No. 12, 12, 2009, p. 5191-5195.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hoffmann, A, Buhk, JH & Strik, H 2009, 'Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.', ANTICANCER RES, vol. 29, no. 12, 12, pp. 5191-5195. <http://www.ncbi.nlm.nih.gov/pubmed/20044635?dopt=Citation>

APA

Hoffmann, A., Buhk, J. H., & Strik, H. (2009). Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. ANTICANCER RES, 29(12), 5191-5195. [12]. http://www.ncbi.nlm.nih.gov/pubmed/20044635?dopt=Citation

Vancouver

Hoffmann A, Buhk JH, Strik H. Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. ANTICANCER RES. 2009;29(12):5191-5195. 12.

Bibtex

@article{c803ee4f93f24db196bd574c834b2ced,
title = "Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.",
abstract = "Patients with neoplastic meningitis (NM) from breast cancer have a median survival of 4-8 months with specific treatment. Here, good tolerance and long-term stabilization with combined intrathecal liposomal cytarabine (Ara-C), which is probably the most promising drug for intrathecal chemotherapy to date, near-continuous temozolomide and radiotherapy is reported in two patients with leptomeningeal and solid central nervous system (CNS) metastases from breast cancer.",
author = "Anna Hoffmann and Buhk, {Jan Hendrik} and H Strik",
year = "2009",
language = "Deutsch",
volume = "29",
pages = "5191--5195",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

RIS

TY - JOUR

T1 - Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide.

AU - Hoffmann, Anna

AU - Buhk, Jan Hendrik

AU - Strik, H

PY - 2009

Y1 - 2009

N2 - Patients with neoplastic meningitis (NM) from breast cancer have a median survival of 4-8 months with specific treatment. Here, good tolerance and long-term stabilization with combined intrathecal liposomal cytarabine (Ara-C), which is probably the most promising drug for intrathecal chemotherapy to date, near-continuous temozolomide and radiotherapy is reported in two patients with leptomeningeal and solid central nervous system (CNS) metastases from breast cancer.

AB - Patients with neoplastic meningitis (NM) from breast cancer have a median survival of 4-8 months with specific treatment. Here, good tolerance and long-term stabilization with combined intrathecal liposomal cytarabine (Ara-C), which is probably the most promising drug for intrathecal chemotherapy to date, near-continuous temozolomide and radiotherapy is reported in two patients with leptomeningeal and solid central nervous system (CNS) metastases from breast cancer.

M3 - SCORING: Zeitschriftenaufsatz

VL - 29

SP - 5191

EP - 5195

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 12

M1 - 12

ER -